Dr Kimberly Smith, Senior Vice President, Chief Scientific Officer, Head of Research & Development at ViiV Healthcare, ...

Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its ...

US biotech Ionis Pharmaceuticals has reported positive top-line data from the Phase III ESSENCE trial of its antisense drug ...

UK pharma major GSK (LSE: GSK) yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala ...

Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label ...

Privately-held French drugmaker Servier and China-based BioNova Pharmaceuticals today announce that they have entered into a ...

The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that ...

Swiss pharma major Roche (ROG: SIX) has reported updated results from its Phase III STARGLO trial, showing that a ...

Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed.

At its May meeting, the European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for three biosimilar medicines: ...

Relief earlier announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare ...